Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

Blood

Volumn 122, Issue 17, 2013, Pages 3020-3029

  Rossi, Edmund A ^a,b   Goldenberg, David M ^a,b,c   Michel, Rosana ^a   Rossi, Diane L ^a   Wallace, Daniel J ^d   Chang, Chien Hsing ^a,b  

^a IMMUNOMEDICS INC   (United States)

^b IBC Pharmaceuticals Inc ^*  (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA7 INTEGRIN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD79B ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; EPRATUZUMAB; FC RECEPTOR; HERMES ANTIGEN; L SELECTIN; ANTINEOPLASTIC AGENT; CD22 PROTEIN, HUMAN; CD79 ANTIGEN; CD79B PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; CELL COMMUNICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DAUDI CELL LINE; EFFECTOR CELL; GRANULOCYTE; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; INTERNALIZATION; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAJI CELL LINE; SYSTEMIC LUPUS ERYTHEMATOSUS; TROGOCYTOSIS; CLINICAL TRIAL (TOPIC); COCULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; IMMUNOLOGY; NONHODGKIN LYMPHOMA; PATHOLOGY; PHAGOCYTOSIS; PRIMARY CELL CULTURE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, NON-HODGKIN;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD19; ANTIGENS, CD79; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; COCULTURE TECHNIQUES; GENE EXPRESSION; GRANULOCYTES; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, NON-HODGKIN; MONOCYTES; PHAGOCYTOSIS; PRIMARY CELL CULTURE; RECEPTORS, COMPLEMENT 3D; SIALIC ACID BINDING IG-LIKE LECTIN 2;

EID: 84885332343     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-473744     Document Type: Article

References (52)

1. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3051-3059.
2. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004;10(16): 5327-5334.
3. Raetz EA, Cairo MS, Borowitz MJ, et al; Children's Oncology Group Pilot Study. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008; 26(22):3756-3762.
4. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129.
5. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8(3):R74.
6. Hobbs K, Wallace D, Strand V, et al. Safety and efficacy of epratuzumab in an open-label extension study (SL0006) [abstract]. Arthritis Rheum. 2012;64(S10):S276.
7. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study [published online ahead of print January 12, 2003]. Ann Rheum Dis.
8. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9(10, pt 2): 3982S-3990S.
9. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007;44(6):1331-1341.
10. Fujimoto M, Sato S. B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity. J Dermatol Sci. 2007;46(1):1-9.
11. Zouali M, Sarmay G. B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum. 2004;50(9):2730-2741.
12. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol. 2003;4(9):815.
13. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006;176(4): 2600-2609.
14. Ahmed KA, Xiang J. Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med. 2011;15(7):1458-1473.
15. Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol. 2007; 7(3):238-243.
16. Rechavi O, Goldstein I, Kloog Y. Intercellular exchange of proteins: the immune cell habit of sharing. FEBS Lett. 2009;583(11):1792-1799.
17. Sprent J. Swapping molecules during cell-cell interactions. Sci STKE. 2005;2005(273):pe8.
18. Ahmed KA, Munegowda MA, Xie Y, Xiang J. Intercellular trogocytosis plays an important role in modulation of immune responses. Cell Mol Immunol. 2008;5(4):261-269.
19. Caumartin J, Lemaoult J, Carosella ED. Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. Transpl Immunol. 2006;17(1):20-22.
20. LeMaoult J, Caumartin J, Daouya M, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007;109(5):2040-2048.
21. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol. 2008;181(11): 8120-8132.
22. Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibodydependent cellular cytotoxicity of rituximabopsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol. 2008;181(4):2916-2924.
23. Boross P, Jansen JH, Pastula A, van der Poel CE, Leusen JH. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. Immunol Lett. 2012; 143(1):44-52.
24. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989;74(7):2527-2534.
25. Carroll MC. CD21/CD35 in B cell activation. Semin Immunol. 1998;10(4):279-286.
26. Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol. 1998;160(4): 1565-1572.
27. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity. 1997;6(2):107-118.
28. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science. 1996;274(5288):798-801.
29. Nitschke L, Carsetti R, Ocker B, Köhler G, Lamers MC. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol. 1997;7(2):133-143.
30. Otipoby KL, Andersson KB, Draves KE, et al. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature. 1996; 384(6610):634-637.
31. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol. 1996; 157(10):4371-4378.
32. Fujimoto M, Kuwano Y, Watanabe R, et al. B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation. J Immunol. 2006; 176(2):873-879.
33. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995;3(1):39-50.
34. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature. 1995;376(6538):352-355.
35. Sato S, Steeber DA, Tedder TF. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc Natl Acad Sci USA. 1995;92(25):11558-11562.
36. Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood. 2008; 111(4):2211-2219.
37. Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med. 1997; 186(11):1923-1931.
38. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000;165(11):6635-6643.
39. Depoil D, Fleire S, Treanor BL, et al. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol. 2008;9(1):63-72.
40. Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(6):R204.
41. Jones JD, Hamilton BJ, Rigby WF. Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum. 2012;64(10): 3111-3118.
42. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol. 2006;177(10):7435-7443.
43. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006;6(5): 394-403.
44. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54(2):613-620.
45. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16): 3823-3837.
46. Aucher A, Magdeleine E, Joly E, Hudrisier D. Capture of plasma membrane fragments from target cells by trogocytosis requires signaling in T cells but not in B cells. Blood. 2008;111(12): 5621-5628.
47. Caumartin J, Favier B, Daouya M, et al. Trogocytosis-based generation of suppressive NK cells. EMBO J. 2007;26(5):1423-1433.
48. Gary R, Voelkl S, Palmisano R, Ullrich E, Bosch JJ, Mackensen A. Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD81 T cells via trogocytosis. J Immunol. 2012;188(2):744-752.
49. McCann FE, Eissmann P, Onfelt B, Leung R, Davis DM. The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences. J Immunol. 2007;178(6):3418-3426.
50. Quah BJ, Barlow VP, McPhun V, Matthaei KI, Hulett MD, Parish CR. Bystander B cells rapidly acquire antigen receptors from activated B cells by membrane transfer. Proc Natl Acad Sci USA. 2008;105(11): 4259-4264.
51. Rafii A, Mirshahi P, Poupot M, et al. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS ONE. 2008;3(12):e3894.
52. Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol. 2006;177(5): 3063-3073.